By Daniel Siegal ( January 31, 2017, 10:25 PM EST) -- A California state appeals court on Monday rejected autoimmune disease drug company Aminopterin LLC's bid to force its contract dispute with its part-owner, PharmaInvest, into arbitration, ruling the arbitration agreement at issue only covers PharmaInvest and the other part-owner, drug developer Syntrix, not Aminopterin itself....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.